Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sight Sciences (SGHT) EBITDA (2020 - 2026)

Sight Sciences has reported EBITDA over the past 6 years, most recently at -$3.7 million for Q4 2025.

  • For Q4 2025, EBITDA rose 69.24% year-over-year to -$3.7 million; the TTM value through Dec 2025 reached -$37.1 million, up 26.58%, while the annual FY2025 figure was -$37.1 million, 26.58% up from the prior year.
  • EBITDA for Q4 2025 was -$3.7 million at Sight Sciences, up from -$7.9 million in the prior quarter.
  • Over five years, EBITDA peaked at -$3.7 million in Q4 2025 and troughed at -$22.9 million in Q2 2022.
  • A 5-year average of -$14.0 million and a median of -$13.6 million in 2023 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: plummeted 106.43% in 2022 and later skyrocketed 69.24% in 2025.
  • Year by year, EBITDA stood at -$14.7 million in 2021, then decreased by 15.88% to -$17.1 million in 2022, then surged by 34.85% to -$11.1 million in 2023, then fell by 7.37% to -$11.9 million in 2024, then skyrocketed by 69.24% to -$3.7 million in 2025.
  • Business Quant data shows EBITDA for SGHT at -$3.7 million in Q4 2025, -$7.9 million in Q3 2025, and -$11.7 million in Q2 2025.